<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641702</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001665</org_study_id>
    <nct_id>NCT04641702</nct_id>
  </id_info>
  <brief_title>Comprehensive Esophageal Diagnostics Study</brief_title>
  <official_title>Comprehensive Assessment of Histopathologic and Physiologic Profile in Esophageal Motility Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective clinical trial will study muscle fibrosis in relation to lower esophageal&#xD;
      sphincter (LES) measurements on Functional Lumen Imaging Probe (FLIP) Topography (the novel&#xD;
      technology that utilizes impedance planimetry) after pharmacologic challenge. A better&#xD;
      understanding of achalasia will allow intervention at an earlier stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Achalasia is a disease characterized by inadequate opening of the lower esophageal sphincter.&#xD;
      Achalasia is presumed to be due to neuronal dysfunction (active), however there are other&#xD;
      variables such as muscle layer fibrosis (passive) that may contribute, particularly in milder&#xD;
      or earlier achalasia variants. A new technology, impedance planimetry, may be able to measure&#xD;
      active vs passive features of the lower esophageal sphincter (LES).&#xD;
&#xD;
      The prospective clinical trial will study muscle fibrosis in relation to lower esophageal&#xD;
      sphincter (LES) measurements on Functional Lumen Imaging Probe (FLIP) Topography (the novel&#xD;
      technology that utilizes impedance planimetry) after pharmacologic challenge. A better&#xD;
      understanding of achalasia will allow intervention at an earlier stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will have the option of consenting for Aim 1(pharmacologic challenge ), Aim 2 (in the event they go for future myotomy) or both if they choose to be included in the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of lower esophageal sphincter contraction and relaxation</measure>
    <time_frame>Two minutes after the study drugs administration</time_frame>
    <description>Degree of lower esophageal sphincter contraction and relaxation will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The collagen content in muscle biopsy specimens</measure>
    <time_frame>Two minutes after the study drugs administration</time_frame>
    <description>The collagen content in muscle biopsy specimens will be measured on Sirius Red and Masson Trichrome staining.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Achalasia</condition>
  <arm_group>
    <arm_group_label>Pharmacologic challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of esophageal response toatropine using functional lumen imaging probe (FLIP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine challenge</intervention_name>
    <description>Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.</description>
    <arm_group_label>Pharmacologic challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophageal muscle biopsy</intervention_name>
    <description>Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.</description>
    <arm_group_label>Pharmacologic challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age 18 and above.&#xD;
&#xD;
          2. Evaluated by Emory Digestive Diseases Clinic, Emory Motility Lab, the Emory Endoscopy&#xD;
             Unit, or Emory Surgery Department from October 1, 2020 to September 30, 2023.&#xD;
&#xD;
          3. Has a diagnosis of achalasia or an esophageal motility disorder with confirmed&#xD;
             evaluation by one of the following modalities: functional lumen imaging probe (FLIP)&#xD;
             or high resolution esophageal manometry (for Aim 1)&#xD;
&#xD;
          4. Undergoing a diagnostic Functional Lumen Imaging Probe (FLIP) study at Emory&#xD;
             University Hospital with anesthesia assistance (for Aim 1)&#xD;
&#xD;
          5. Undergoing Heller myotomy or per oral endoscopic myotomy for treatment of their&#xD;
             esophageal motility disorder (for Aim 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 years old&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Prisoners&#xD;
&#xD;
          4. Non-English speaking - the rationale is that the symptom characterization and outcome&#xD;
             data are measured on detailed and fairly lengthy (5-7 pages) of questionnaires written&#xD;
             in English with some medical terms. These are standardized questionnaires and do not&#xD;
             have short forms available.&#xD;
&#xD;
          5. Cognitively impaired adults unable to provide informed consent&#xD;
&#xD;
          6. Cardiac disease in the form of - arrhythmia requiring ICD or pacemaker, baseline&#xD;
             bradycardia with HR &lt;60 or tachycardia with HR &gt; 90, congestive heart failure with&#xD;
             ejection fraction &lt;35%, history of myocardial infarction, baseline MAP &lt;65 or systolic&#xD;
             BP &gt;140, asthma or chronic obstructive pulmonary disease, urinary retention requiring&#xD;
             use of foley catheterization (including intermittent use), narrow angle glaucoma,&#xD;
             myasthenia gravis, GFR &lt;60 [exclusions for Aim 1 only]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anand Jain, MD</last_name>
    <phone>404-778-3184</phone>
    <email>anand.jain@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Anand Jain</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lower esophageal sphincter</keyword>
  <keyword>Functional Lumen Imaging Probe Topography</keyword>
  <keyword>anti-fibrosis agents</keyword>
  <keyword>anti-inflammatory agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Achalasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Esophageal function testing data, symptom questionnaire data, treatments performed, and biospecimen analysis results will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Estimated January 2024.</ipd_time_frame>
    <ipd_access_criteria>Collaborators with whom the study team has Data Use Agreements in Place will have access through secure electronic means.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

